Cancer is a sneaky disease. Find one method of treating it successfully, and it finds another way to survive. Take, for example, pediatric diffuse midline gliomas, brain tumors that are among the most ...

A new editorial perspective was published in Oncotarget, titled "STAT3 as a biologically relevant target in H3K27M-mutant diffuse midline glioma." Pediatric H3K27M-mutant diffuse midline gliomas (DMGs ...

Dordaviprone targets mitochondrial protease and dopamine receptor D2, representing a novel approach in cancer therapy for H3 K27M-mutant diffuse glioma. The drug application seeks accelerated FDA ...

Diffuse gliomas are malignant brain tumors and cannot be optimally examined by conventional imaging using MRI. Amino acid PET can better visualize the activity and spread of gliomas. An international ...

Please provide your email address to receive an email when new articles are posted on . A patient’s frailty should be considered when determining fractionation for WHO grade 4 adult-type diffuse ...

What Is Modeyso, and Why Does It Matter? Modeyso (dordaviprone) is a new oral medicine that treats a rare and aggressive brain tumor, called diffuse midline glioma (DMG), that has a tumor mutation ...

Diffuse intrinsic pontine glioma (DIPG) is an almost universally fatal brain pediatric tumor and the only tumor indication where palliative radiotherapy is the current standard of care. Although ...

Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a ...

Dordaviprone has been granted Priority Review by the FDA for recurrent H3 K27M-mutant diffuse glioma, with a target action date of August 18. The drug has received Rare Pediatric Disease, Fast-Track, ...